Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.52 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.52 |
| ▸ | AR | P10275 | 6/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.44 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29615609 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL4857820 | 0.88 | AR (0.53) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL29778091 | 0.87 | ALDH1A1 (0.47) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL7050401 | 0.83 | MAOA (0.61) | ALDH1A1KDM4EARMAOAMAOB | |
| SCHEMBL31441456 | 0.83 | MAOA (0.61) | ALDH1A1KDM4EARMAOAMAOB | |
| SCHEMBL7691509 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4EUSP2IMPDH2IMPDH1 | |
| SCHEMBL10202601 | 0.81 | NOS2 (0.43) | ALDH1A1KDM4EUSP2ARMAOA | |
| SCHEMBL16957005 | 0.80 | PTGDR2 (0.44) | ALDH1A1KDM4EUSP2HPGDPTGDR2 | |
| SCHEMBL95805 | 0.80 | PTGDR2 (0.48) | ALDH1A1KDM4EHPGDPTGDR2 | |
| SCHEMBL3042839 | 0.80 | PTGDR2 (0.44) | ALDH1A1KDM4EUSP2HPGDPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-221492478-U | Reaction and feeding integrated device for producing 5-chloro-2-methoxyl benzonitrile | 南京安淮创新药物研究院有限公司 | 2024-08-09 | — | — | CN | claimed |
| EP-4267555-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | claimed |
| WO-2022117678-A1 | OCTAHYDROISOQUINOLINYL DERIVATIVES | UCB Biopharma SRL (BE) | 2022-06-09 | — | — | WO | claimed |
| US-12415793-B2 | Modulators of TMEM16A for treating respiratory disease | TMEM16A LIMITED (GB) | 2025-09-16 | — | — | US | disclosed |
| CN-118724752-A | Tyrosine kinase inhibitor intermediate, preparation method and application thereof | 重庆博腾制药科技股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-221514416-U | Solid material adding device for producing 5-chloro-2-methoxyl benzonitrile | 南京安淮创新药物研究院有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-221492478-U | Reaction and feeding integrated device for producing 5-chloro-2-methoxyl benzonitrile | 南京安淮创新药物研究院有限公司 | 2024-08-09 | — | — | CN | disclosed |
| CN-114269433-B | Modulators of TMEM16A for the treatment of respiratory diseases | TMEM16A有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-114989103-B | Preparation method of 2-methoxy-3- (1-methyl-1H-1, 2, 4-triazole-3-yl) aniline | 杭州科巢生物科技有限公司 | 2024-07-09 | — | — | CN | disclosed |
| CN-118184591-A | Preparation method of 2-methoxy-3- (1-methyl-1H-1, 2, 4-triazole-3-yl) aniline | 上海工程技术大学 | 2024-06-14 | — | — | CN | disclosed |
| US-20240132467-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TMEM16A LIMITED (GB) | 2024-04-25 | — | — | US | disclosed |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | GRUENENTHAL GMBH (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20060068428-A1 | Identification of genetic markers associated with parkinson disease | DUKE UNIVERSITY | 2006-03-30 | — | — | US | disclosed |
| EP-1216257-B1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040198693-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2004-10-07 | — | — | US | disclosed |
| US-20040087798-A1 | Novel amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1264820-A1 | NOVEL AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| EP-1216257-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | Pfizer Products Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001023399-A1 | COMPOUNDS FOR THE TREATMENT OF ISCHEMIA | PFIZER PRODUCTS INC. (US) | 2001-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12415793-B2 | Modulators of TMEM16A for treating respiratory disease | TMEM109, CFTR, TMEM120A | ALDH1A1 691/4885KDM4E 3220/4885USP2 3117/4885 |
| US-20080176915-A1 | Substituted Benzo[d]isoxazol-3-yl Amine Compounds as Analgesics | KCNQ1, KCNQ2, KCNQ3 | ALDH1A1 1965/4885KDM4E 276/4885USP2 4265/4885 |
| US-20240132467-A1 | BENZIMIDAZOLE DERIVATIVES FOR TREATING RESPIRATORY DISEASE | TMEM109, CFTR, TMEM164 | ALDH1A1 330/4885KDM4E 2522/4885USP2 3619/4885 |
| US-20040087798-A1 | Novel amide compounds | H1-2, H1-0, H1-3 | ALDH1A1 1144/4885KDM4E 1506/4885USP2 4276/4885 |
| US-20040198693-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ALDH1A1 1085/4885KDM4E 4221/4885USP2 4152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.